September 17, 2020
On August 5, 2020, the Federal Drug Administration (FDA) announced a voluntary recall by Ferring US on all lots of DDAVP (desmopressin acetate) nasal spray (10mcg/0.1mL, 5mL), desmopressin acetate nasal spray (10mcg/0.1mL, 5mL), and STIMATE nasal spray (1.5mg/mL, 2.5mL).
The voluntary recall is due to superpotency, amounts of desmopressin higher than specified. Excessive amounts of desmopressin could (in severe cases) result in seizure, coma, or death. To date, Ferring US hasn’t received an increase in adverse event reports due to increased concentrations of desmopressin from patients.
Members with a prescription should continue to take it as directed and contact their prescribing provider for alternative treatment options. A new prescription isn’t required. Preferred alternatives are available for the same out-of-pocket cost. Costs may vary however depending on the replacement prescription and policies of the dispensing pharmacy.
For more information on this recall, read the FDA announcement.